Germany Drug Delivery Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type (IInhalation Drug Delivery, Injectable Drug Delivery, Nasal Drug Delivery, Oral Drug Delivery, Transdermal Drug Delivery), By Application (Treatment of Diseases, Research/Academic Purposes), And By Geography - Forecasts From 2022 To 2027

The German Drug Delivery Market is expected to grow at a compound annual growth rate of 7.02% over the forecast period to reach a market size of US$45.209 billion in 2027, from US$28.119 billion in 2020.

Drug Delivery refers to a process through which drugs or therapeutic chemicals are presented into the human body either manually or through the drug delivery systems through oral, nasal, or skin contact. Increasing research and development in the pharmaceutical sector, increased public spending, and growing chronic diseases like cardiovascular disease, cancer, diabetes, neurological disorders, etc., are a few of the significant drivers for the German drug delivery market. 

Growing Biologics Sector:

The growing biologics sector is one of the key contributors to the growing German drug delivery market. Biologics are a special type of drug that slows or stops damaging inflammation. Biologics are a special type of Disease-Modifying Antirheumatic Drug (DMARD) prescribed only when conventional DMARDs don’t work. The development of biological drugs has led to a substantial shift in the drug industry, especially when big pharma conglomerates are shifting from small molecular drugs to biologic drugs. As per a report by Germany Trade and Invest, from 2015 to 2019, the biologics market grew by nearly 11.6%, which was more than twice the growth of the pharma market on an overall basis.

Chronic Diseases:

The growing prevalence of chronic diseases due to the increasing consumption of alcohol and tobacco remains the primary cause of death in Germany which has paved for the development of the drug delivery market in the region. As per WHO, one-third of Germans are addicted to binge drinking, and these statistics are higher than that of Europe. WHO says that Ischaemic Heart disease and stroke are the primary cause of death in the country, and around 3 in 5 Germans are affected by chronic diseases in their later life. With these statistics and reports, chronic disease remains a primary issue of concern for the German Government. The rise of chronic disease is a significant driver of the drug delivery market.

Increasing Research and Development to play a key role in the German drug delivery market:

Increasing research and development investments for drug delivery are expected to be a significant driver for the industry in the coming years. In 2019, Germany ranked fifth worldwide by registering a total of 499 clinical trials which were financed by research-based pharmaceutical companies.  Germany has witnessed continuous growth in its research and development budget over the years. As per the data available from World Bank, Germany spent nearly 3.133% of GDP on Research and Development expenditure in 2018, one of the highest budget allowances given to this sector by any country. Research and development in pharmaceuticals and drugs have always played an important role in the development of drug delivery solutions. For instance, recently, Novo Nordisk invested $5 million in the CHUM Foundation for an integrated research and care institute for diabetes.

Impact of COVID-19 Pandemic on the German Drug Delivery Market:

With the outbreak of the first wave, the country’s drug market witnessed a loss. The panic buying of medicines like antivirals, vitamin tablets, etc., led to a sudden increase in demand which overpowered the supply chains. Nevertheless, with time and heavy investments in research and vaccine development, the German drug-delivery companies bounced back to their original state. The short-term impact of the pandemic was almost recovered with the supplies back online and the pharmaceutical companies back into the production business. 

Germany Drug Delivery Market Scope:

Segmentation:

• By Type
  • Inhalation Drug Delivery
  • Injectable Drug Delivery
  • Nasal Drug Delivery
  • Oral Drug Delivery
  • Transdermal Drug Delivery
• By Application
  • Treatment of diseases
  • Research/Academic purposes

1. INTRODUCTION
1.1. Market Overview
1.2. Covid-19 Scenario
1.3. Market Definition
1.4. Market Segmentation

2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY
3.1. Research Highlights

4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. GERMANY DRUG DELIVERY MARKET ANALYSIS, BY TYPE
5.1. Introduction
5.2. Inhalation Drug Delivery
5.3. Injectable Drug Delivery
5.4. Nasal Drug Delivery
5.5. Oral Drug Delivery
5.6. Transdermal Drug Delivery

6. GERMANY DRUG DELIVERY MARKET ANALYSIS, BY APPLICATION
6.1. Introduction
6.2. Treatment of diseases
6.3. Research/Academic purposes

7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2.  Emerging Players and Market Lucrativeness
7.3.  Mergers, Acquisitions, Agreements, and Collaborations
7.4.  Vendor Competitiveness Matrix

8. COMPANY PROFILES
8.1. Novartis
8.2. Roche Holding AG
8.3. Bayer
8.4. Boehringer-Ingelheim
8.5. Novo Nordisk
8.6. Bristol Myers Squibb
8.7. GlaxoSmithKline

Novartis

Roche Holding AG

Bayer

Boehringer-Ingelheim

Novo Nordisk

Bristol Myers Squibb

GlaxoSmithKline